2024-07-16 05:30:00 ET
Summary
- TimesSquare Capital U.S. Small Cap Growth portfolio outperformed the Russell 2000® Growth Index in the second quarter.
- The portfolio outperformed the Russell Midcap Growth Index in the second quarter.
- Pulling back by -27% was Legend Biotech, a biotechnology developer of cell therapies to treat blood cancers such as multiple myeloma and leukemia.
- At the midway point of 2024, as expected, fields of vision were occupied by central banks and election booths.
Performance | ||||||
Annualized | ||||||
2Q24 | 1YR | 3YR | 5YR | 7YR | 10YR | |
FOCUS Growth Equity Composite (Gross) | 0.08% | 25.82% | 10.13% | 16.41% | 16.65% | 13.04% |
FOCUS Growth Equity Composite (Net) | -0.13% | 24.68% | 9.07% | 15.29% | 15.52% | 11.93% |
Russell Midcap® Growth Index | -3.21% | 15.05% | -0.08% | 9.92% | 11.68% | 10.51% |
Read the full article on Seeking Alpha
For further details see:
TimesSquare Capital U.S. FOCUS Growth Equity Q2 2024 Commentary